Sirtex
Sirtex develops and delivers oncology treatments using novel small particle technology to improve outcomes for patients with cancer. SIR-Spheres® Y-90 resin microspheres target liver tumors with radiation via the hepatic artery during Selective Internal Radiation Therapy (SIRT). Data shared at ASCO showed a 7.9 month improvement in Progression-Free Survival in the liver for patients with unresectable mCRC treated first line with SIR-Spheres Y-90 resin microspheres plus standard chemotherapy.